Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

NCT00694083 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm

Interventions

DRUG: Ridaforolimus

Sponsor

Merck Sharp & Dohme LLC